WO2010110993A3 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer Download PDF

Info

Publication number
WO2010110993A3
WO2010110993A3 PCT/US2010/025801 US2010025801W WO2010110993A3 WO 2010110993 A3 WO2010110993 A3 WO 2010110993A3 US 2010025801 W US2010025801 W US 2010025801W WO 2010110993 A3 WO2010110993 A3 WO 2010110993A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cancer
cancers
isolated
compounds
Prior art date
Application number
PCT/US2010/025801
Other languages
French (fr)
Other versions
WO2010110993A2 (en
Inventor
Isaac Cohen
Original Assignee
Bionovo, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/553,878 external-priority patent/US20100069480A1/en
Application filed by Bionovo, Inc. filed Critical Bionovo, Inc.
Priority to AU2010229167A priority Critical patent/AU2010229167A1/en
Priority to CA2756452A priority patent/CA2756452A1/en
Priority to JP2012502070A priority patent/JP2012521424A/en
Priority to EP10756546A priority patent/EP2411031A4/en
Publication of WO2010110993A2 publication Critical patent/WO2010110993A2/en
Publication of WO2010110993A3 publication Critical patent/WO2010110993A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Isolated compounds and combinations of isolated compounds isolated from Scutellaria barbata D. Don are effective in the generation of reactive oxygen species, induction of DNA damage and induction of apoptosis in cancer cells. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans, for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers.
PCT/US2010/025801 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer WO2010110993A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2010229167A AU2010229167A1 (en) 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer
CA2756452A CA2756452A1 (en) 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer
JP2012502070A JP2012521424A (en) 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer
EP10756546A EP2411031A4 (en) 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16298809P 2009-03-24 2009-03-24
US61/162,988 2009-03-24
US17263909P 2009-04-24 2009-04-24
US61/172,639 2009-04-24
US12/553,878 US20100069480A1 (en) 2008-09-03 2009-09-03 Methods and compositions for the treatment of cancer
US12/553,878 2009-09-03

Publications (2)

Publication Number Publication Date
WO2010110993A2 WO2010110993A2 (en) 2010-09-30
WO2010110993A3 true WO2010110993A3 (en) 2011-01-13

Family

ID=42781750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/025801 WO2010110993A2 (en) 2009-03-24 2010-03-01 Methods and compositions for the treatment of cancer

Country Status (5)

Country Link
EP (1) EP2411031A4 (en)
JP (1) JP2012521424A (en)
AU (1) AU2010229167A1 (en)
CA (1) CA2756452A1 (en)
WO (1) WO2010110993A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599237B (en) * 2013-11-28 2015-06-03 姜永华 Traditional Chinese medicine for treating gastric cancer of stasis in stomach collateral type and preparation method thereof
EP3476227A4 (en) * 2016-06-24 2020-02-05 Suntory Holdings Limited Composition for browning inhibition and use of same
CN110346494B (en) * 2019-06-03 2021-09-28 云南农业大学 Method for simultaneously measuring contents of 4 effective components in erigeron breviscapus
CN113018347B (en) * 2021-03-01 2022-07-22 中国药科大学 Traditional Chinese medicine extract nanoparticle and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437866A (en) * 1989-11-03 1995-08-01 Sun; Alexander S. Herbal treatment of malignancy
US6294526B1 (en) * 1998-02-06 2001-09-25 Alps Pharmaceutical Ind. Co., Ltd. Use of flavone derivatives for induction of β-lactam-sensitivity of MRSA
US20070110832A1 (en) * 2005-11-14 2007-05-17 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009289644A1 (en) * 2008-09-03 2010-03-11 Bionovo, Inc. Methods and compositions for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437866A (en) * 1989-11-03 1995-08-01 Sun; Alexander S. Herbal treatment of malignancy
US6294526B1 (en) * 1998-02-06 2001-09-25 Alps Pharmaceutical Ind. Co., Ltd. Use of flavone derivatives for induction of β-lactam-sensitivity of MRSA
US20070110832A1 (en) * 2005-11-14 2007-05-17 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2411031A4 *

Also Published As

Publication number Publication date
WO2010110993A2 (en) 2010-09-30
CA2756452A1 (en) 2010-09-30
EP2411031A2 (en) 2012-02-01
AU2010229167A1 (en) 2011-10-20
JP2012521424A (en) 2012-09-13
EP2411031A4 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
WO2010028187A3 (en) Methods and compositions for the treatment of cancer
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2013036543A3 (en) Molecular imaging of cancer cells in vivo
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX370721B (en) Novel compounds and compositions for targeting cancer stem cells.
WO2012033525A3 (en) P53-mdm2 antagonists
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
WO2011083088A3 (en) Methods for treating colorectal cancer
WO2010101964A3 (en) Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell
WO2011083090A3 (en) Methods for treating breast cancer
MD20160016A2 (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
WO2009070244A3 (en) Methods for inhibiting fascin
WO2011020107A3 (en) Compositions and methods for detection and treatment of breast cancer
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2009070478A3 (en) A process of making purified extract of scutellaria barbata d. don
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2010110993A3 (en) Methods and compositions for the treatment of cancer
WO2011100642A3 (en) Method for treating hematological cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756546

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012502070

Country of ref document: JP

Ref document number: 2756452

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010229167

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010229167

Country of ref document: AU

Date of ref document: 20100301

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010756546

Country of ref document: EP